NewsEvents

Your Yourlocation: Home > Many patients with severe chronic obstructive pulmonary disease may not need to add ICS based on tiotropium bromide(136310-93-5) and LABA

Peter Calverley, professor of respiratory and rehabilitation medicine at the University of Liverpool, UK, said in the course of the findings of the WISDOM study: "The results of the study show that many patients with severe or severe chronic obstructive pulmonary disease may not need to be based on tiotropium bromide(136310-93-5) and LABA. It is good news to add ICS, and if so, these patients will be able to avoid the potential for adverse reactions associated with ICS treatment, including increased risk of pneumonia and osteoporosis."

The data from the study, WISDOM study results are also published in the "New England Journal of Medicine" published. WISDOM study evaluated the effect of discontinuing ICS on the basis of Sliverine® and LABA in patients with severe and extremely severe chronic obstructive pulmonary disease with acute exacerbations. For these patients, the GOLD guidelines recommend ICS based on long-acting bronchodilator therapy.

WISDOM findings suggest that many patients with chronic obstructive pulmonary disease may not be able to benefit from the addition of an ICS treatment based on Si Lihua ® and LABA treatment in moderate to severe acute exacerbations.

The main end result of the WISDOM study showed that patients who continued to receive ICS treatment in patients with severe dyspepsia with a history of acute exacerbation were treated with SiLiHua plus LABA baseline maintenance regimen with discontinued ICS patients with considerable moderate /severe acute exacerbations.

After the final discontinuation of ICS, there was an increase in the number of severe severe acute exacerbations, but this situation was not maintained throughout the course of the study.

Address: TEL:0531-82375879 Tiotropium Bromide
© Copyright(C)2014 JINAN DEXINJIA BIO & TECH CO., LTD All Rights Reserved